6 Results for "

Spike (S) glycoprotein receptor binding domain

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "Spike (S) glycoprotein receptor binding domain" in MCE Product Catalog:

Cat. No.: HY-P99467
CAS No.: 2423016-74-2
Synonyms: BMS 4182137; VIR 7832

Target:  

SARS-CoV

Research Areas:  

Infection

Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
loading...
    loading...
Cat. No.: HY-P99104
CAS No.: 2529854-88-2
Synonyms: COVI-AMG; STI-2020

Target:  

SARS-CoV

Research Areas:  

Infection

Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
loading...
    loading...
Cat. No.: HY-145641
CAS No.: 2599039-61-7
Synonyms: BMS-986413; C-144-LS

Target:  

SARS-CoV

Research Areas:  

Infection

Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
loading...
    loading...
Cat. No.: HY-P990052
CAS No.: 2657609-23-7
Synonyms: MAD-0004J08

Target:  

SARS-CoV

Research Areas:  

Infection

Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
loading...
    loading...
Cat. No.: HY-P991491

Research Areas:  

Infection

VIR-7229 is a human IgG1 monoclonal antibody (mAb) targeting Receptor-Binding Domain, RBD, Spike glycoprotein. VIR-7229 exerts antiviral activity by competing with ACE2 for binding and inducing S1 protein shedding. VIR-7229 can be used in SARS-CoV-2 infection research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-145644
CAS No.: 2599039-60-6
Synonyms: C-135-LS; BMS-986414

Target:  

SARS-CoV

Research Areas:  

Infection Cancer

Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
loading...
    loading...